Carregant...
Anticancer Activity of Novel NF-κB Inhibitor DHMEQ by Intraperitoneal Administration
There have been great advances in the therapy of cancer and leukemia. However, there are still many neoplastic diseases that are difficult to treat. For example, it is often difficult to find effective therapies for aggressive cancer and leukemia. An NF-κB inhibitor named dehydroxymethylepoxyquinomi...
Guardat en:
| Publicat a: | Oncol Res |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Cognizant Communication Corporation
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7751220/ https://ncbi.nlm.nih.gov/pubmed/32576339 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504020X15929100013698 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|